Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS | ALC Stock News

Author's Avatar
Apr 25, 2025
Article's Main Image
  • Alcon introduces UNITY VCS and CS, advancing vitreoretinal and cataract surgery efficiency.
  • UNITY 4D Phaco technology offers up to twice the speed in nucleus removal with 41% less energy.
  • The new systems will be available in Australia, Europe, Japan, and the U.S. starting May 2025.

Alcon, a leading name in eye care, has unveiled the UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS), presenting a groundbreaking leap in the efficiency of vitreoretinal and cataract surgeries. This latest innovation introduces two configurations: a combined console (VCS) and a standalone cataract system (CS), aiming to deliver exceptional patient outcomes with enhanced surgical efficiency.

Key features of UNITY VCS/CS include the HYPERVIT 30K, recognized as the world's fastest vitrectomy probe executing an impressive 30,000 cuts per minute. This is complemented by the UNITY 4D Phaco technology, which allows for nucleus removal at twice the usual speed while using 41% less energy.

Alcon’s UNITY Intelligent Fluidics is another highlight, offering improved pressure and flow control, thus ensuring surgical stability. The company plans to start shipping these products to key markets, including Australia, Europe, Japan, and the U.S., from May onwards, with an expansion to other regions expected in the third quarter of 2025, pending regulatory approvals.

UNITY VCS/CS will be exhibited at the 2025 American Society for Cataract and Refractive Surgeons annual meeting (ASCRS) in Los Angeles, allowing surgeons an opportunity for hands-on experience with the platform. This launch marks the first release within Alcon’s new UNITY portfolio, set to advance surgical equipment solutions in the ophthalmic sector.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.